Anthem Biosciences IPO: What GMP signals ahead of listing on Monday
is set to debut on the stock exchanges on Monday, July 21. In the unlisted market, its shares are trading at a premium of Rs 165–170, indicating a potential listing gain of around 29% over the IPO price of Rs 570 (upper band).
While the grey market premium (GMP) reflects strong investor interest, it remains a speculative indicator and can change quickly before listing.
Explore courses from Top Institutes in
Select a Course Category
others
Healthcare
Leadership
Finance
Data Science
Design Thinking
healthcare
Technology
Others
PGDM
Operations Management
Degree
Digital Marketing
Cybersecurity
MCA
Management
Product Management
Artificial Intelligence
Data Science
CXO
Public Policy
Project Management
Data Analytics
MBA
Skills you'll gain:
Duration:
16 Weeks
Indian School of Business
CERT - ISB Cybersecurity for Leaders Program India
Starts on
undefined
Get Details
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Average Cost To Rent A Private Jet May Surprise You (View Prices)
Private Jet I Search Ads
Learn More
Undo
The Rs 3,395 crore IPO was entirely an offer for sale (OFS) and closed on July 16. It witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times.
The issue was priced in a band of Rs 540–570 per share, with a minimum lot size of 26 shares. The stock will list on both NSE and BSE.
About Anthem Biosciences
Founded in 2006, Anthem Biosciences operates in a niche segment of the pharma value chain, offering end-to-end drug discovery, development, and manufacturing services. It is among the few Indian CRDMOs with integrated capabilities across both small molecules (chemical-based) and large molecules (biologics).
Live Events
Its differentiated fee-for-service (FFS) model has enabled it to cater to small and mid-sized biotech firms globally, which constitute a large portion of its client base. Since its inception, the company has served over 675 clients and completed more than 8,000 projects.
In FY25, Anthem reported strong financials, with an EBITDA margin of 36.8% and a Return on Net Worth (RoNW) of 20.8%. As of March 2025, the company's net worth stood at Rs 2,410 crore.
Its facilities are cGMP-compliant and approved by global regulatory bodies such as the USFDA, ANVISA, TGA, and PMDA. The company is currently expanding its fermentation and synthesis capacities to meet growing demand for complex biologics and specialty ingredients.
JM Financial
is the book-running lead manager of the
Anthem Biosciences IPO
, while
Kfin Technologies
is the registrar for the issue.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
21 minutes ago
- Hindustan Times
'Donald Trump's tariffs could push India closer to…': Ex-US NSA John Bolton warns president
Former US National Security Advisor John Bolton has warned that President Donald Trump's tariff measures against India, intended to hurt Russia, could end up having the opposite effect by pushing New Delhi closer to Moscow and Beijing. US President Donald Trump has slapped an additional 25 per cent tariff on goods coming from India as penalty for New Delhi's continued buying of Russian oil.(PTI file) "Trump's tariffs against India are intended to hurt Russia but they could push India closer to Russia and to China to oppose these tariffs," John Bolton told CNN in an interview. The former NSA further cautioned, 'Trump's leniency on the Chinese, and heavy-handed tariffs on India, jeopardise decades of American efforts to bring India away from Russia and China.' In an opinion piece for The Hill, Bolton said Trump's approach of favouring China over India on trade is 'an enormous mistake and entirely counterproductive for America". He argued that the tariffs do not align with America's long-term geopolitical goals, as the US is 'levying tariffs on friend and foe alike". "Unfortunately, based on international reactions so far, the U.S. by levying tariffs on friend and foe alike has likely suffered a considerable loss of trust and confidence, built up over decades of effort, in exchange for minimal economic gains — if any — and the risk of formidable losses," he wrote. Bolton claimed the White House 'seems headed toward more-lenient treatment for Beijing on tariff rates and other metrics than it imposed on New Delhi,' warning that 'if so, it will be a potentially enormous mistake.' He noted that Treasury Secretary Scott Bessent has suggested China's August 12 deadline could be extended if negotiations appeared promising. "Trump announced on July 30 that India's tariff rate would be 26 percent, 1 point lower than originally proposed on Apr. 2, but a major increase from the previous average rate of 2.4 percent. Moreover, Trump harshly criticized India's acquisition of Russian military equipment, underlining a longstanding U.S.-India disagreement, and Indian purchases of Russian oil and gas in violation of America's Ukraine-related sanctions. (India is also one of the BRICS countries, which Trump separately singled out for a 10 percent tariff.)," Bolton wrote. He warned that resentment in India could escalate if China secured a better trade arrangement. "China runs a significantly larger trade surplus with the U.S. than does India. Washington has also long complained about Chinese trade practices, which include stealing intellectual property, unfairly subsidizing its international companies and denying access to China's domestic market, contrary to repeated commitments," Bolton said. Donald Trump has announced a 50% tariff on Indian exports, penalising the country for its Russian oil imports. India and Brazil share the top spot among countries on the US tariff list. Trump's decision to punish India came as negotiations between the two countries on a trade deal were expected to conclude. The US president's remarks that India's economy as 'dead' and its tariff barriers 'obnoxious' further strained relations between the two countries. India's external affairs ministry termed the imposition of additional tariffs as 'extremely unfortunate' as other countries also trade with the Russian Federation.
India.com
21 minutes ago
- India.com
Revealed: This Indian private company bought the most oil from Russia, the name is..., now tariff may affect profit and margin both
Revealed: This Indian private company bought the most oil from Russia, the name is..., now tariff may affect profit and margin both As the Indian government continues to gauge the impact of additional 25 per cent tariff, total 50 per cent, announced by US President Donald Trump, the Indian company, which is the largest buyer of Russian oil, has warned of far reaching consequences of Washington's arbitrary decision. According to a report, Reliance Industries is India's largest buyer of Russian crude oil. Reliance Industries, in its annual report for the year ending March 2025, underlined that global crude oil prices remained volatile due to geopolitical tension in the Middle East, shifting shipping routes, OPEC and non-OPEC output decisions and other reasons. However, the company did not mention US tariff imposition in the report. India historically bought most of its oil from the Middle East, including Iraq and Saudi Arabia. However, things changed when Russia invaded Ukraine in February 2022. India, the world's third-largest crude importer after China and the US, began snapping up Russian oil that was available at a discount after some in the West shunned it as a means to punish Moscow for its invasion of Ukraine. Why has Trump singled out India? Earlier this week, US President Donald Trump on slapped an additional 25 per cent tariff, raising it to 50 per cent, on goods coming from India as penalty for New Delhi's continued purchase of Russian oil, a move that is likely to hit sectors such as textiles, marine and leather exports hard. The United States has imposed this additional tariff or penalty for Russian imports only on India while other buyers such as China and Turkey have so far escaped such measures. The 30 per cent tariff on China and 15 per cent on Turkey is lower than India's 50 per cent. What is Trump's stance? Donald Trump stated that trade negotiations with India will not proceed until the ongoing tariff dispute is resolved, after his administration decided to double tariffs on Indian imports. When pressed by news agency ANI at the Oval Office, whether he expected talks to resume in light of the new 50% tariff. 'No, not until we get it resolved,' he replied.
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
Sebi proposes new lighter-touch approach for accredited investors for AIFs
The Securities and Exchange Board of India (Sebi) has proposed a separate type of alternative investment fund (AIF) scheme that would admit only "accredited investors". Such AIF schemes will get the benefit of a lighter regulatory framework. Sebi's latest consultation paper has proposed a gradual transition from the traditional minimum commitment threshold (currently at Rs 1 crore per investor) to using only accreditation status as the metric for investor sophistication in AIFs. During the transition, both metrics would coexist, enabling AIFs to launch special schemes, open exclusively to accredited investors, who are deemed better to assess risk and conduct due diligence, the regulator has proposed. Other benefits include extended tenure, where the scheme tenure may be extended up to five years, subject to approval by two-thirds of investors by value in the fund. Also, such schemes will get 'certification waiver', where key investment team members may be exempt from holding a mandated NISM certification, given investors' ability to conduct independent due diligence. Further, there will be no investor cap for such schemes, allowing them to bypass the existing limit of 1,000 investors per scheme. Also, in trust structures, managerial duty may assume those responsibilities typically assigned to trustees, subject to contractual terms. These relaxations mirror those already available to so-called 'large value funds' AIFs target sophisticated investors with higher risk appetites. Sebi had introduced the 'accredited investor' framework in 2021, allowing investors meeting strict income and net worth criteria to invest with greater flexibility. While the current count of accredited investors is modest, Sebi expects growth due to recent regulatory changes and further simplification of the accreditation process. The regulator believes that the proposed framework will help the AIF industry pivot towards an accredited investors-only segment.
